5-甲氧基-2,1-苯并氧杂硼l-1(3H)-醇 | 174671-92-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 5-甲氧基-2,1-苯并氧杂硼l-1(3H)-醇
• 英文名称: 5-methoxybenzo[c][1,2]oxaborol-1(3H)-ol
• 英文别名: 2,1-Benzoxaborole, 1,3-dihydro-1-hydroxy-5-methoxy-；1-hydroxy-5-methoxy-3H-2,1-benzoxaborole
• CAS: 174671-92-2
• 化学式: C₈H₉BO₃
• mdl: MFCD10699480
• 分子量: 163.969
• InChiKey: XBCBZHBKJDEYCI-UHFFFAOYSA-N

物化性质

• 熔点：
  102-104 °C(Solv: hexane (110-54-3))
• 沸点：
  288.8±50.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.85
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-甲氧基-2,1-苯并氧杂硼l-1(3H)-醇 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 生成 1,3-二氢-2,1-苯并恶唑-1,5-二醇
  参考文献：
  名称：

  Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease

  摘要：

  We disclose here a series of P4-benzoxaborole-substituted macrocyclic HCV protease inhibitors. These inhibitors are potent against HCV NS3 protease, their anti-HCV replicon potencies are largely impacted by substitutions on benzoxaborole ring system and P2* groups. P2* 2-thiazole-isoquinoline provides best replicon potency. The in vitro SAR studies and in vivo PK evaluations of selected compounds are described herein. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.10.071
• 作为产物：
  描述：

  2-溴-5-甲氧基苯甲酸 在 盐酸 、 正丁基锂 、 硼烷四氢呋喃络合物 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 为溶剂， 反应 2.25h， 生成 5-甲氧基-2,1-苯并氧杂硼l-1(3H)-醇
  参考文献：
  名称：

  Discovery of a New Boron-Containing Antifungal Agent, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1- benzoxaborole (AN2690), for the Potential Treatment of Onychomycosis

  摘要：

  A structure-activity relationship investigation for a more efficacious therapy to treat onychomycosis, a fungal infection of the toe and fingernails, led to the discovery of a boron-containing small molecule, 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2690), which is currently in clinical trials for onychomycosis topical treatment.

  DOI：

  10.1021/jm0603724

文献信息

• Widely Exploited, Yet Unreported: Regiocontrolled Synthesis and the Suzuki-Miyaura Reactions of Bromooxazole Building Blocks
  作者：Vitalii V. Solomin、Dmytro S. Radchenko、Evgeniy Y. Slobodyanyuk、Oleksandr V. Geraschenko、Bohdan V. Vashchenko、Oleksandr O. Grygorenko

  DOI：10.1002/ejoc.201900032

  日期：2019.5.15

  An approach to synthesis of all isomeric bromooxazoles was optimized and its scope was extended to all three isomeric parents, as well as various alkyl‐ and aryl‐substituted bromooxazoles. The direct regiocontrolled lithiation followed by reaction with electrophilic bromine source was common and led exclusively to the target substituted 2‐, 4‐, and 5‐bromooxazoles on multigram scale. The utility of

  优化了所有异构体溴恶唑的合成方法，并将其范围扩展到所有三个异构体母体，以及各种烷基和芳基取代的溴恶唑。直接区位控制的锂化反应，随后与亲电溴源反应是很常见的现象，并且仅在毫克数范围内导致目标取代的2-，4-和5-溴恶唑。在平行合成条件下，Suzuki-Miyaura交叉偶联反应证明了在这项工作中获得的多功能构建基块的效用。
• Oxaboroles and salts thereof, and their use as biocides
  申请人：Zeneca Limited

  公开号：US05880188A1

  公开（公告）日：1999-03-09

  A method for the protection of a medium by susceptible to microbial attack by the treatment of the medium with an oxaborale or a salt of an oxaborale.

  通过使用氧硼烷或氧硼烷的盐处理介质，来保护易受微生物侵袭的介质的方法。
• Substituent Effects on Oxidation-Induced Formation of Quinone Methides from Arylboronic Ester Precursors
  作者：Sheng Cao、Robin Christiansen、Xiaohua Peng

  DOI：10.1002/chem.201300539

  日期：2013.7.1

  efficiently generate QMs under physiological conditions. Finally, a quantitative relationship between the structure and activity has been established for the arylboronic esters by using a Hammett plot. The reactivity of the arylboronic acids/esters and the inhibition or facilitation of QM formation can now be predictably adjusted. This adjustment is important as some applications may benefit and others

  一系列含有不同芳族取代基和各种苄基离去基团（BR或N-芳基硼酸酯的+我3溴- ）已被合成。已经研究了取代基对其与H 2 O 2的反应性和甲基化醌（QM）形成的影响。NMR光谱和乙基乙烯基醚（EVE）捕获实验分别用于确定反应机理和QM形成。在硼酸酯的氧化裂解过程中不会产生QM，而是在生理条件下通过苯酚产物的后续转化产生的。吸电子取代基（例如芳族F，NO 2或苄基N ）促进了氧化脱硼+我3溴- ，而给电子取代基或更好的离去基团有利于QM产生。包含芳香族CH 3或OMe基团或良好离去基团（Br）的化合物可在生理条件下有效产生QM。最后，通过使用哈米特图建立了芳基硼酸酯的结构与活性之间的定量关系。现在可以预测地调整芳基硼酸/酯的反应性以及抑制或促进QM的形成。此调整很重要，因为某些应用程序可能会受益，而其他应用程序可能会受到QM生成的限制。
• Transition-metal-free, one-pot synthesis of benzoxaboroles from <i>o</i>-bromobenzaldehydes <i>via</i> visible-light-promoted borylation
  作者：Jinghan Luo、Xingxing Jia、Yanjun Hu、Jianchao Chen、Tiemin Sun

  DOI：10.1039/d1ob01853a

  日期：——

  A novel and simple one-pot stepwise method to synthesize benzoxaboroles was demonstrated. This step-by-step synthetic method includes photocatalytic boronization with phenothiazine as a photocatalyst and sequential water-induced reduction in the presence of bis(pinacolato)diboron. A series of o-bromobenzaldehydes were well-tolerated under the standard conditions. In addition, this method has been successfully

  展示了一种新颖且简单的一锅法逐步合成苯并恶硼烷的方法。这种分步合成方法包括使用吩噻嗪作为光催化剂的光催化硼化和在双（频哪醇）二硼存在下的连续水诱导还原。一系列邻溴苯甲醛在标准条件下具有良好的耐受性。此外，该方法已成功应用于抗结核候选药物GSK 3036656和抗真菌药物tavaborole的合成。
• Pentacyclic oxepines and derivatives thereof, compositions and methods
  申请人：Hinklin Jay Ronald

  公开号：US20050261277A1

  公开（公告）日：2005-11-24

  The present invention provides a compound of the formula (I) wherein R 1 is —H, —OH, —O(C 1 -C 4 alkyl), —OCOC —OCO(C 1 -C 6 alkyl), or —OSO 2 (C 2 -C 6 alkyl); R 0 , R 2 and R 3 are each independently —H, —OH, —O(C 1 -C 4 alkyl), —OCOC 6 H 5 , —OCO(C 1 -C 6 alkyl), —OSO 2 (C 2 -C 6 alkyl)or halo; R 4 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, diisopropylamino, or 1-hexamethyleneimino; n is 2 or 3 X is —S— or —HC═H—; G is —O—, —S—, —SO—, SO 2 , or —N(R 5 )—, wherein R 5 is —H or C 1 -C 4 alkyl; and Y is —O—, —S—, —NH—, —NMe—, or —CH 2 —; or a pharmaceutically acceptable salt thereof; pharmaceutical compositions thereof, optionally in combination with estrogen and progestin; methods of inhibiting a disease associated with estrogen deprivation; and methods for inhibiting a disease associated with an aberrant physiological response to endogenous estrogen.

  本发明提供了式（I）的化合物，其中R1为—H，—OH，—O（C1-C4烷基），—OCOC—OCO（C1-C6烷基）或—OSO2（C2-C6烷基）; R0，R2和R3各自独立地为—H，—OH，—O（C1-C4烷基），—OCOC6H5，—OCO（C1-C6烷基），—OSO2（C2-C6烷基）或卤素; R4为1-哌啶基，1-吡咯烷基，甲基-1-吡咯烷基，二甲基-1-吡咯烷基，4-吗啉基，二甲氨基，二乙氨基，二异丙基氨基或1-己亚甲基亚胺基; n为2或3，X为—S—或—HC═H—; G为—O—，—S—，—SO—，SO2或—N（R5）—，其中R5为—H或C1-C4烷基; Y为—O—，—S—，—NH—，—NMe—或—CH2—; 或其药学上可接受的盐; 其药物组合物，可选与雌激素和孕激素联合使用; 抑制与雌激素缺乏相关的疾病的方法; 以及抑制与内源性雌激素异常生理反应相关的疾病的方法。